KNTPF (Kintor Pharmaceutical) Other Stockholders Equity : $40.35 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Other Stockholders Equity?

Kintor Pharmaceutical's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $40.35 Mil.

Kintor Pharmaceutical's quarterly Other Stockholders Equity declined from Dec. 2023 ($64.12 Mil) to Jun. 2024 ($2.20 Mil) but then increased from Jun. 2024 ($2.20 Mil) to Dec. 2024 ($40.35 Mil).

Kintor Pharmaceutical's annual Other Stockholders Equity declined from Dec. 2022 ($214.42 Mil) to Dec. 2023 ($64.12 Mil) and declined from Dec. 2023 ($64.12 Mil) to Dec. 2024 ($40.35 Mil).

Kintor Pharmaceutical Other Stockholders Equity Historical Data

The historical data trend for Kintor Pharmaceutical's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Other Stockholders Equity Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Get a 7-Day Free Trial

4.30

10.28

214.42

64.12

40.35

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial								214.42	11.79	64.12	2.20	40.35

Kintor Pharmaceutical Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Kintor Pharmaceutical Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

09939:Hong Kong

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.